Key facts
- This page summarizes Kevin Kotler's Form 3 filing for HERON THERAPEUTICS, INC. /DE/ (HRTX).
- 0 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 02 Mar 2023, 15:13.
Kevin Kotler - 22 Feb 2023 Form 3 Insider Report for HERON THERAPEUTICS, INC. /DE/ (HRTX)
- Reporting relationship
- Director
- Issuer ticker
- HRTX
- Reported as of
- 22 Feb 2023
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 02 Mar 2023, 15:13:38 UTC
- Prior SEC filing
- 22 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lisa Peraza Attorney-in-fact for Kevin Kotler
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Kevin Kotler filed Form 3 for HERON THERAPEUTICS, INC. /DE/ (HRTX) on 02 Mar 2023.
Change
- Previous filing in this sequence was filed on 22 Mar 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HRTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 37,879
- Date
- 22 Feb 2023
- Ownership
- Direct
- Footnotes
- F1
HRTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 540,000
- Date
- 22 Feb 2023
- Ownership
- By Broadfin Holdings LLC
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
HRTX
holding
Derivative
Stock Option (Right to Buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 22 Feb 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 227,272
- Exercise price
- $2.70
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The shares were granted as restricted stock units which vest in 16 equal quarterly installments beginning one quarter after the date of grant (02/22/2023).
Footnote F2
The stock option vests and becomes exercisable in 48 equal monthly installments beginning one month after the date of grant (02/22/2023).